NEW YORK, Sept. 18, 2019 /PRNewswire/ -- The Global Companion Diagnostics Market size is expected to reach $6.5 billion by 2025, rising at a market growth of 19.9% CAGR during the forecast period.
Read the full report: https://www.reportlinker.com/p05815657/?utm_source=PRN
A companion diagnostics test is done to understand which patient can gain benefits from a specific drug or decide upon the kind of dosage that should be prescribed. All of this, on the basis of a patient's clinical diagnosis, which offers required evidence for the successful and harmless utilization of an equivalent biological or drug product to treat the medical issue. These can also be referred to as medical instruments that help doctors in electing which dosage or treatment is sufficient for patients and suits to their necessity.
The growth of research and development activities in the genetic sciences and biomarkers leads to new drug development mechanisms, dominated by companion diagnostics in the personalized medicine phase. Moreover, the development and usage of companion diagnostics have considerably improved the knowledge of the molecular causes of illnesses, the identification of many biomarkers and the development of targeted treatment.Based on Technology, the market is segmented into Immunohistochemistry, Polymerase chain reaction (PCR), Next generation sequencing (NGS), In Situ Hybridization, and Other Technology. Based on Indication, the market is segmented into Oncology, Neurology and Other Indications. Further based on Cancer Type, the Oncology market is segmented into Breast Cancer, Colorectal Cancer, Lung Cancer, Blood Cancer and Other Cancer Type. Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa.The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Agilent Technologies, Inc., Almac Group, ARUP Laboratories, Inc., Abbott Laboratories (Abbott Laboratories Molecular, Inc.), Danaher Corporation, Thermo Fisher Scientific, Inc., Hologic, Inc., Novartis AG, Illumina, Inc., Qiagen N.V.Scope of the StudyMarket Segmentation:By Technology• Immunohistochemistry• Polymerase chain reaction (PCR)• Next generation sequencing (NGS)• In Situ Hybridization and• Other TechnologyBy Indication• Oncology• Neurology and• Other IndicationsBy Cancer Type• Breast Cancer• Colorectal Cancer• Lung Cancer• Blood Cancer and• Other Cancer TypeBy Geography• North Americao USo Canadao Mexicoo Rest of North America• Europeo Germanyo UKo Franceo Russiao Spaino Italyo Rest of Europe• Asia Pacifico Chinao Japano Indiao South Koreao Singaporeo Australiao Rest of Asia Pacific• LAMEAo Brazilo Argentinao UAEo Saudi Arabiao South Africao Nigeriao Rest of LAMEACompanies Profiled• Agilent Technologies, Inc.• Almac Group• ARUP Laboratories, Inc.• Abbott Laboratories (Abbott Laboratories Molecular, Inc.)• Danaher Corporation• Thermo Fisher Scientific, Inc.• Hologic, Inc.• Novartis AG• Illumina, Inc.• Qiagen N.V.Unique Offerings • Exhaustive coverage• Highest number of market tables and figures• Subscription based model available• Guaranteed best price• Assured post sales research support with 10% customization freeRead the full report: https://www.reportlinker.com/p05815657/?utm_source=PRN About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ Contact Clare: [email protected] US: (339)-368-6001 Intl: +1 339-368-6001
Advertisement
Read the full report: https://www.reportlinker.com/p05815657/?utm_source=PRN
A companion diagnostics test is done to understand which patient can gain benefits from a specific drug or decide upon the kind of dosage that should be prescribed. All of this, on the basis of a patient's clinical diagnosis, which offers required evidence for the successful and harmless utilization of an equivalent biological or drug product to treat the medical issue. These can also be referred to as medical instruments that help doctors in electing which dosage or treatment is sufficient for patients and suits to their necessity.
Advertisement
The growth of research and development activities in the genetic sciences and biomarkers leads to new drug development mechanisms, dominated by companion diagnostics in the personalized medicine phase. Moreover, the development and usage of companion diagnostics have considerably improved the knowledge of the molecular causes of illnesses, the identification of many biomarkers and the development of targeted treatment.Based on Technology, the market is segmented into Immunohistochemistry, Polymerase chain reaction (PCR), Next generation sequencing (NGS), In Situ Hybridization, and Other Technology. Based on Indication, the market is segmented into Oncology, Neurology and Other Indications. Further based on Cancer Type, the Oncology market is segmented into Breast Cancer, Colorectal Cancer, Lung Cancer, Blood Cancer and Other Cancer Type. Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa.The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Agilent Technologies, Inc., Almac Group, ARUP Laboratories, Inc., Abbott Laboratories (Abbott Laboratories Molecular, Inc.), Danaher Corporation, Thermo Fisher Scientific, Inc., Hologic, Inc., Novartis AG, Illumina, Inc., Qiagen N.V.Scope of the StudyMarket Segmentation:By Technology• Immunohistochemistry• Polymerase chain reaction (PCR)• Next generation sequencing (NGS)• In Situ Hybridization and• Other TechnologyBy Indication• Oncology• Neurology and• Other IndicationsBy Cancer Type• Breast Cancer• Colorectal Cancer• Lung Cancer• Blood Cancer and• Other Cancer TypeBy Geography• North Americao USo Canadao Mexicoo Rest of North America• Europeo Germanyo UKo Franceo Russiao Spaino Italyo Rest of Europe• Asia Pacifico Chinao Japano Indiao South Koreao Singaporeo Australiao Rest of Asia Pacific• LAMEAo Brazilo Argentinao UAEo Saudi Arabiao South Africao Nigeriao Rest of LAMEACompanies Profiled• Agilent Technologies, Inc.• Almac Group• ARUP Laboratories, Inc.• Abbott Laboratories (Abbott Laboratories Molecular, Inc.)• Danaher Corporation• Thermo Fisher Scientific, Inc.• Hologic, Inc.• Novartis AG• Illumina, Inc.• Qiagen N.V.Unique Offerings • Exhaustive coverage• Highest number of market tables and figures• Subscription based model available• Guaranteed best price• Assured post sales research support with 10% customization freeRead the full report: https://www.reportlinker.com/p05815657/?utm_source=PRN About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ Contact Clare: [email protected] US: (339)-368-6001 Intl: +1 339-368-6001
View original content:http://www.prnewswire.com/news-releases/the-global-companion-diagnostics-market-size-is-expected-to-reach-6-5-billion-by-2025--rising-at-a-market-growth-of-19-9-cagr-during-the-forecast-period-300920857.html
SOURCE Reportlinker
